Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28633214 | 0.97 | SIGMAR1 (0.41) | SIGMAR1HTR1AALDH1A1PKMPARP1 | |
| SCHEMBL18412338 | 0.93 | SIGMAR1 (0.47) | SIGMAR1PARP1 | |
| SCHEMBL4827565 | 0.87 | DRD2 (0.53) | SIGMAR1HTR1AALDH1A1PKMDRD2 | |
| SCHEMBL24489448 | 0.85 | SIGMAR1 (0.48) | SIGMAR1HTR1AALDH1A1PKMDRD2 | |
| SCHEMBL4826031 | 0.83 | HTR1A (0.41) | SIGMAR1HTR1AALDH1A1PKMDRD2 | |
| SCHEMBL18396148 | 0.83 | DRD2 (0.49) | SIGMAR1HTR1AALDH1A1PKMDRD2 | |
| SCHEMBL18408688 | 0.82 | DRD2 (0.45) | SIGMAR1HTR1AALDH1A1PKMPARP1 | |
| SCHEMBL18408680 | 0.80 | ALDH1A1 (0.47) | SIGMAR1ALDH1A1PKMDRD2 | |
| SCHEMBL17411300 | 0.79 | HTR1A (0.51) | SIGMAR1HTR1ADRD2 | |
| SCHEMBL29363627 | 0.77 | SIGMAR1 (0.60) | SIGMAR1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2019-01-31 | — | — | US | claimed |
| EP-3160470-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Teva Pharmaceutical Industries Ltd (IL) | 2017-05-03 | — | — | EP | claimed |
| WO-2016003919-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-01-07 | — | — | WO | claimed |
| EP-4049998-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd. (IL) | 2022-08-31 | — | — | EP | disclosed |
| EP-3160470-B1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd (IL) | 2022-08-03 | — | — | EP | disclosed |
| EP-3325443-B1 | PROCESS FOR PREPARING PRIDOPIDINE | Prilenia Neurotherapeutics Ltd (IL) | 2022-06-08 | — | — | EP | disclosed |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2022-01-27 | — | — | US | disclosed |
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2021-10-12 | — | — | US | disclosed |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2020-01-30 | — | — | US | disclosed |
| US-10406145-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2019-09-10 | — | — | US | disclosed |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2019-01-31 | — | — | US | disclosed |
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2018-11-20 | — | — | US | disclosed |
| EP-3160470-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Teva Pharmaceutical Industries Ltd (IL) | 2017-05-03 | — | — | EP | disclosed |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | US | disclosed |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2016003919-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-01-07 | — | — | WO | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PDE7A, PDE3A, PDE4D | SIGMAR1 267/4885HTR1A 150/4885ALDH1A1 3318/4885 |
| US-10406145-B2 | Analogs of pridopidine, their preparation and use | QDPR, DRD2, OPRD1 | SIGMAR1 12/4885HTR1A 72/4885ALDH1A1 981/4885 |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | PDE6D, QDPR, PDE4D | SIGMAR1 826/4885HTR1A 465/4885ALDH1A1 2847/4885 |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | SIGMAR1 14/4885HTR1A 93/4885ALDH1A1 919/4885 |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PDE3A, PDE4D, PDE9A | SIGMAR1 142/4885HTR1A 228/4885ALDH1A1 2432/4885 |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | SIGMAR1 12/4885HTR1A 72/4885ALDH1A1 981/4885 |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | SIGMAR1 14/4885HTR1A 66/4885ALDH1A1 906/4885 |
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | QDPR, DRD2, OPRD1 | SIGMAR1 14/4885HTR1A 66/4885ALDH1A1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.